Investors Asset Management of Georgia’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-83,275
| Closed | -$1.79M | – | 183 |
|
|
2025
Q4 | $1.79M | Sell |
83,275
-48,900
| -37% | -$949K | 0.74% | 40 |
|
|
2025
Q3 | $2.02M | Sell |
132,175
-900
| -0.7% | -$11.7K | 0.86% | 32 |
|
|
2025
Q2 | $1.18M | Sell |
133,075
-6,900
| -5% | -$60.6K | 0.55% | 53 |
|
|
2025
Q1 | $1.1M | Buy |
139,975
+19,700
| +16% | +$165K | 0.55% | 54 |
|
|
2024
Q4 | $1.26M | Buy |
120,275
+21,200
| +21% | +$257K | 0.62% | 49 |
|
|
2024
Q3 | $1.3M | Buy |
99,075
+9,600
| +11% | +$146K | 0.61% | 49 |
|
|
2024
Q2 | $1.26M | Buy |
89,475
+2,100
| +2% | +$34.2K | 0.61% | 52 |
|
|
2024
Q1 | $1.48M | Sell |
87,375
-19,100
| -18% | -$284K | 0.69% | 46 |
|
|
2023
Q4 | $1.5M | Buy |
+106,475
| New | +$1.25M | 0.76% | 43 |
|
|
2023
Q3 | – | Sell |
-93,975
| Closed | -$1.55M | – | 165 |
|
|
2023
Q2 | $1.55M | Sell |
93,975
-36,831
| -28% | -$479K | 0.8% | 33 |
|
|
2023
Q1 | $1.2M | Sell |
130,806
-7,500
| -5% | -$61.7K | 0.64% | 47 |
|
|
2022
Q4 | $990K | Sell |
138,306
-2,269
| -2% | -$15.9K | 0.52% | 58 |
|
|
2022
Q3 | $704K | Buy |
140,575
+700
| +0.5% | +$3.85K | 0.36% | 72 |
|
|
2022
Q2 | $341K | Buy |
139,875
+46,500
| +50% | +$191K | 0.18% | 114 |
|
|
2022
Q1 | $638K | Buy |
93,375
+6,700
| +8% | +$46.1K | 0.32% | 85 |
|
|
2021
Q4 | $700K | Buy |
86,675
+16,400
| +23% | +$150K | 0.33% | 78 |
|
|
2021
Q3 | $689K | Buy |
70,275
+7,500
| +12% | +$59.1K | 0.36% | 73 |
|
|
2021
Q2 | $422K | Buy |
62,775
+7,150
| +13% | +$56.8K | 0.23% | 105 |
|
|
2021
Q1 | $503K | Buy |
+55,625
| New | +$450K | 0.29% | 90 |
|
|
2020
Q4 | – | Sell |
-53,325
| Closed | -$269K | – | 142 |
|
|
2020
Q3 | $269K | Buy |
53,325
+17,125
| +47% | +$125K | 0.18% | 110 |
|
|
2020
Q2 | $292K | Buy |
36,200
+3,600
| +11% | +$31.7K | 0.2% | 103 |
|
|
2020
Q1 | $259K | Sell |
32,600
-3,500
| -10% | -$26.9K | 0.21% | 101 |
|
|
2019
Q4 | $273K | Hold |
36,100
| – | – | 0.17% | 128 |
|
|
2019
Q3 | $150K | Buy |
36,100
+3,000
| +9% | +$7.51K | 0.1% | 144 |
|
|
2019
Q2 | $96K | Sell |
33,100
-1,650
| -5% | -$2.84K | 0.06% | 144 |
|
|
2019
Q1 | $50K | Buy |
34,750
+500
| +1% | +$1.13K | 0.03% | 141 |
|
|
2018
Q4 | $88K | Buy |
34,250
+2,000
| +6% | +$6.8K | 0.07% | 138 |
|
|
2018
Q3 | $142K | Buy |
32,250
+8,800
| +38% | +$47.5K | 0.1% | 144 |
|
|
2018
Q2 | $144K | Buy |
23,450
+8,400
| +56% | +$58.9K | 0.11% | 139 |
|
|
2018
Q1 | $110K | Buy |
15,050
+4,700
| +45% | +$41.3K | 0.08% | 144 |
|
|
2017
Q4 | $85K | Sell |
10,350
-700
| -6% | -$6.56K | 0.06% | 144 |
|
|
2017
Q3 | $116K | Hold |
11,050
| – | – | 0.09% | 140 |
|
|
2017
Q2 | $122K | Hold |
11,050
| – | – | 0.08% | 139 |
|
|
2017
Q1 | $107K | Buy |
+11,050
| New | +$110K | 0.07% | 144 |
|
Other funds holding AVDL
Investors Asset Management of Georgia's AVDL Position: Q1 2026 in Review
Investors Asset Management of Georgia sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 83,275 shares — an estimated $1.79M sold.
Investors Asset Management of Georgia first reported a position in AVDL in Q1 2017 and held it in 34 quarters. The position peaked at $2.02M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Investors Asset Management of Georgia reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Investors Asset Management of Georgia sold 83,275 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.79M.
- Investors Asset Management of Georgia first reported a position in Avadel Pharmaceuticals in Q1 2017 and held it in 34 quarters.
- Investors Asset Management of Georgia's Avadel Pharmaceuticals position peaked at $2.02M in Q3 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Investors Asset Management of Georgia's 13F filing for Q1 2026, filed 27 Apr 2026.